“…Aptamers, already the focus of interest for antiviral treatment, including for SARS‐CoV (Esposito et al, 2020 ; Jeon et al, 2004 ; Musafia et al, 2014 ; Song et al, 2020 ; Torabi et al, 2020 ), have at least in some cases the chance to be not only absolutely specific for one epitope but to also show (some) affinity with several oligonucleotide‐binding‐susceptible sequence sections for different proteins of the virus (Esposito et al, 2020 ; Tucker et al, 2012 ; Weisshoff et al, 2020 ). This way, a cumulative multi‐effect might result (multi‐mode of action), together increasing the chance of treatment success.…”